| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
|
Lancet Infect Dis
|
2011
|
3.58
|
|
2
|
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
|
Lancet
|
2006
|
2.85
|
|
3
|
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
|
Lancet Infect Dis
|
2011
|
2.66
|
|
4
|
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
|
Lancet
|
2010
|
2.63
|
|
5
|
Immune reconstitution inflammatory syndrome: incidence and implications for mortality.
|
AIDS
|
2012
|
1.88
|
|
6
|
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
|
J Infect Dis
|
2005
|
1.88
|
|
7
|
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
|
J Acquir Immune Defic Syndr
|
2006
|
1.77
|
|
8
|
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
|
J Acquir Immune Defic Syndr
|
2009
|
1.62
|
|
9
|
Kidney disease in patients with HIV infection and AIDS.
|
Clin Infect Dis
|
2008
|
1.25
|
|
10
|
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
|
AIDS
|
2010
|
1.17
|
|
11
|
Provider guidance for linking patients to antiretroviral therapy adherence interventions: recommendations from an IAPAC advisory committee on adherence monitoring and support.
|
J Int Assoc Provid AIDS Care
|
2013
|
0.96
|
|
12
|
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
|
HIV Clin Trials
|
2012
|
0.95
|
|
13
|
Are health related outcomes in acute pancreatitis improving? An analysis of national trends in the U.S. from 1997 to 2003.
|
JOP
|
2008
|
0.93
|
|
14
|
Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.91
|
|
15
|
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
|
HIV Clin Trials
|
2010
|
0.91
|
|
16
|
Low bone mineral density and risk of incident fracture in HIV-infected adults.
|
Antivir Ther
|
2015
|
0.87
|
|
17
|
Adherence to antiretroviral therapy in an urban, free-care HIV clinic in Guatemala City, Guatemala.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2010
|
0.86
|
|
18
|
Retention in care within 1 year of initial HIV care visit in a multisite US cohort: who's in and who's out?
|
J Int Assoc Provid AIDS Care
|
2014
|
0.84
|
|
19
|
Changes in the use of HIV antiretroviral resistance testing in a large cohort of U.S. patients, 1999 to 2006.
|
J Acquir Immune Defic Syndr
|
2010
|
0.81
|
|
20
|
Use of screening colonoscopy in ambulatory HIV-infected patients.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2008
|
0.80
|
|
21
|
Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.80
|
|
22
|
Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis.
|
Am J Gastroenterol
|
2013
|
0.80
|
|
23
|
Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008.
|
AIDS Res Treat
|
2012
|
0.79
|
|
24
|
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
|
HIV Clin Trials
|
2015
|
0.78
|
|
25
|
Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.
|
AIDS Patient Care STDS
|
2009
|
0.78
|
|
26
|
Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?
|
Curr Opin HIV AIDS
|
2016
|
0.77
|
|
27
|
Bones, Fractures, Antiretroviral Therapy and HIV.
|
Curr Infect Dis Rep
|
2014
|
0.77
|
|
28
|
Generalized multidimensional dynamic allocation method.
|
Stat Med
|
2012
|
0.76
|
|
29
|
Achieving improvements across the HIV treatment cascade: a clinical management algorithm based on IAPAC's entry into and retention in care and antiretroviral therapy adherence guidelines.
|
J Int Assoc Provid AIDS Care
|
2013
|
0.76
|
|
30
|
Author response.
|
Vet Radiol Ultrasound
|
2014
|
0.75
|
|
31
|
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
|
HIV Clin Trials
|
2010
|
0.75
|
|
32
|
An automated mobile phase preparation workstation.
|
J Chromatogr A
|
2006
|
0.75
|
|
33
|
What is your diagnosis? Chronic wooden foreign body.
|
J Am Vet Med Assoc
|
2012
|
0.75
|